Drug delivery systems as immunomodulators for therapy of infectious disease: Relevance to COVID-19.

ABSTRACT: The emergence of SARS-CoV-2, and the ensuing global pandemic, has resulted in an unprecedented response to identify therapies that can limit uncontrolled inflammation observed in patients with moderate to severe COVID-19. The immune pathology behind COVID-19 is complex and involves the activation and interaction of multiple systems including, but not limited to, complement, inflammasomes, endothelial as well as innate and adaptive immune cells to bring about a convoluted profile of inflammation, coagulation and tissue damage. To date, therapeutic approaches have focussed on inhibition of coagulation, untargeted immune suppression and/or cytokine-directed blocking agents. Regardless of recently achieved improvements in individual patient outcomes and survival rates, improved and focussed ap

SUBMITTER: Brain D 

PROVIDER: S-EPMC8233062 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature